Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities
January 10, 2025 09:26 ET
|
Y-mAbs Therapeutics, Inc.
Company establishes two business units with goal of accelerating clinical development of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA Preliminary Part A data...
Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit
January 10, 2025 07:35 ET
|
Y-mAbs Therapeutics, Inc.
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Provides Strategic Business Update and 2025 Priorities
January 10, 2025 07:05 ET
|
Y-mAbs Therapeutics, Inc.
Company establishes two business units with goal of accelerating the advancement of its Radiopharmaceuticals Platform and optimizing the commercial potential of DANYELZA Preliminary Part A data...
Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 23, 2024 07:30 ET
|
Y-mAbs Therapeutics, Inc.
NEW YORK, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting
December 07, 2024 12:00 ET
|
Y-mAbs Therapeutics, Inc.
NEW YORK, Dec. 07, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs to Participate at Citi’s 2024 Global Healthcare Conference
November 27, 2024 07:35 ET
|
Y-mAbs Therapeutics, Inc.
NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments
November 08, 2024 06:35 ET
|
Y-mAbs Therapeutics, Inc.
Reported Total DANYELZA net product revenues of $18.5 million for the third quarter of 2024Entered into exclusive license and distribution agreement with Nobelpharma for DANYELZA in Japan recognizing...
Y-mAbs and Nobelpharma Announce Exclusive License and Distribution Agreement for DANYELZA® (naxitamab-gqgk) in Japan
November 04, 2024 07:35 ET
|
Y-mAbs Therapeutics, Inc.
NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs Announces Third Quarter 2024 Conference Call and Webcast
October 25, 2024 07:05 ET
|
Y-mAbs Therapeutics, Inc.
NEW YORK, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...
Y-mAbs to Participate in Upcoming Investor Conferences in October
October 01, 2024 07:05 ET
|
Y-mAbs Therapeutics, Inc.
NEW YORK, Oct. 01, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and...